Navigation Links
Predicting Breast Cancer Recurrence By Understanding Gene Signature

Researchers say they have now identified a group of genes known as a gene signature, that could help single out which breast cancer patients may be at high risk for having a future cancer recurrence .//

For the study the gene expressions in 286 tumor samples from 209 lymph-node-negative breast cancer patients were examined. The patients had not received hormone or chemotherapy after their initial cancer treatment and varied in age and in their tumor sizes.

Results analyzed, after a follow-up averaging eight years, showed 93 of the women had cancer that spread to another part of their body. Through analyzing 115 of the tumors, researchers identified a 76-gene signature that could predict cancer relapse. The gene signature was tested on 171 lymph-node-negative patients in the study and it predicted (with a 93-percent sensitivity) which patients would have a cancer recurrence within five years. However the test was less accurate (with a 46-percent sensitivity) at predicting cancer recurrence beyond five years.

Since some studies identifying gene signatures for breast cancer recurrence do not identify the same groups of genes when compared, researchers say it becomes difficult to determine which gene signature test to trust. Thus in conclusion researchers say if further studies are done it could help determine better treatment plans for cancer patients .
'"/>




Page: 1

Related medicine news :

1. Predicting The Risk Of Preeclampsia During Pregnancy
2. Predicting The Risk Of A Heart Attack
3. Predicting Severity Of Appendicitis With Computed Tomography
4. Predicting The Risk Of Breast Cancer In The Future
5. Predicting The Risk Of Osteoarthritis
6. Researchers Find Mix of Biomarkers Predicting Mortality
7. Biomarkers Predicting Mortality Found Using Statistical Technique
8. HIV RNA Level Seen As Little Value In Predicting Treatment
9. Predicting the Dynamics of Clotting in Human Blood
10. Follicle Count Test as Good as Hormone Tests in Predicting Ovarian Response
11. Consensus on "Combination Therapy" for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... NEW YORK (PRWEB) , ... March 28, 2017 ... ... development, NTX Technology™, is the first technology to directly address the resolution to ... Organization. NTX Technology™ is a patented compound of FDA and TTB approved ingredients ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/28/2017)... LONDON , March 28, 2017  "US ... insight on the various indicators and trend analysis ... generics drugs in mainstream pharmaceutical market in US. ... responsible for the growth on cancer generics drugs ... resulted in saving of billions of dollars for ...
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
Breaking Medicine Technology: